Respirology,O
Case,O
Reports,O
What,O
happens,O
when,O
we,O
treat,O
the,O
Typhoid,CAUSE_OF_DEATH
Mary,PERSON
of,PERSON
Boon,PERSON
Hau,PERSON
Ng1,O
.,O
Nik,PERSON
Nuratiqah,PERSON
Nik,PERSON
Abeed1,PERSON
.,O
Mohamed,PERSON
Faisal,PERSON
Abdul,PERSON
Hamid1,PERSON
Hsueh,PERSON
Jing,PERSON
Low2,PERSON
&,O
Yu,PERSON
‐,PERSON
Lin,PERSON
Andrea,PERSON
Ban1,PERSON
.,O
Chun,PERSON
Ian,PERSON
Soo1,PERSON
Pulmonology,O
Unit,O
.,O
Department,ORGANIZATION
of,ORGANIZATION
Internal,ORGANIZATION
Medicine,ORGANIZATION
.,O
Faculty,O
of,O
Medicine,O
.,O
Universiti,LOCATION
Kebangsaan,LOCATION
Malaysia,COUNTRY
Medical,O
Centre,O
.,O
Kuala,LOCATION
Lumpur,LOCATION
.,O
Malaysia,COUNTRY
.,O
Department,O
of,O
Anesthesiology,O
and,O
Intensive,O
Care,O
.,O
Faculty,ORGANIZATION
of,ORGANIZATION
Medicine,ORGANIZATION
.,O
Universiti,ORGANIZATION
Kebangsaan,ORGANIZATION
Malaysia,ORGANIZATION
Medical,ORGANIZATION
Centre,O
.,O
Kuala,CITY
Lumpur,CITY
.,O
Malaysia,COUNTRY
.,O
Computed,O
tomography,O
.,O
COVID,O
‐,O
19,NUMBER
.,O
ground,O
‐,O
glass,O
opacication,O
.,O
pneumonia,CAUSE_OF_DEATH
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Yu,PERSON
‐,PERSON
Lin,PERSON
Andrea,PERSON
Ban,O
.,O
Pulmonology,ORGANIZATION
Unit,ORGANIZATION
.,O
Department,ORGANIZATION
of,ORGANIZATION
Internal,ORGANIZATION
Medicine,ORGANIZATION
.,O
Faculty,O
of,O
Medicine,MISC
.,O
Universiti,LOCATION
Kebangsaan,LOCATION
Malaysia,COUNTRY
Medical,O
Centre,O
.,O
Jalan,PERSON
Yaacob,PERSON
Latif,PERSON
.,O
Bandar,PERSON
Tun,PERSON
Razak,PERSON
.,O
Cheras,LOCATION
.,O
56000,NUMBER
Kuala,PERSON
Keang,PERSON
Lim,PERSON
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
in,O
‐,O
fection,O
was,O
declared,O
a,O
pandemic,O
on,O
11,DATE
March,DATE
2020,DATE
.,O
We,O
have,O
since,O
seen,O
its,O
fast,O
spread,O
worldwide,O
.,O
A,O
likely,O
contributing,O
factor,O
was,O
the,O
lack,O
of,O
symptoms,O
of,O
some,O
of,O
the,O
carriers,O
.,O
making,O
them,O
unaware,O
of,O
their,O
risk,O
of,O
spreading,O
to,O
other,O
more,O
vulnerable,O
individuals,O
.,O
The,O
other,O
important,O
nding,O
has,O
been,O
the,O
reported,O
cases,O
of,O
infec,O
‐,O
tivity,O
despite,O
lack,O
of,O
symptoms,O
.,O
We,O
describe,O
the,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
pneu,O
‐,O
monia,O
patterns,O
in,O
asymptomatic,O
individuals,O
.,O
The,O
common,O
computed,O
tomography,O
(,O
CT,STATE_OR_PROVINCE
),O
thorax,O
patterns,O
found,O
are,O
peripheral,O
ground,O
‐,O
glass,O
opacication,O
(,O
GGO,O
),O
with,O
upper,O
or,O
lower,O
lobe,O
predominance,O
.,O
We,O
be,O
‐,O
lieve,O
screening,O
for,O
2019,DATE
‐,O
novel,O
coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
high,O
‐,O
risk,O
individuals,O
may,O
help,O
identify,O
the,O
patients,O
needing,O
longer,O
follow,O
‐,O
up,O
.,O
Respirology,O
Case,O
Reports,O
.,O
8,NUMBER
(,O
6,NUMBER
),O
.,O
2020,DATE
.,O
e00604,NUMBER
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARSCoV,O
‐,O
2,NUMBER
),O
infection,CAUSE_OF_DEATH
was,O
declared,O
a,O
pandemic,O
by,O
the,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
on,O
11,NUMBER
March,DATE
2020,DATE
.,O
2019,DATE
‐,O
Novel,O
coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
is,O
a,O
positive,O
sin,O
‐,O
gle,O
‐,O
stranded,O
RNA,O
virus,O
belonging,O
to,O
the,O
‐,O
coronavirus,O
cluster,O
.,O
To,O
date,O
.,O
two,NUMBER
fatal,O
respiratory,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
in,O
human,O
history,O
are,O
SARS,O
in,O
2002,DATE
and,O
Middle,LOCATION
East,LOCATION
respiratory,O
syndrome,O
(,O
MERS,O
),O
in,O
2012,DATE
.,O
Case,O
Series,O
An,O
asymptomatic,O
45,NUMBER
‐,O
year,DURATION
‐,O
old,O
woman,O
with,O
no,O
known,O
medical,O
illness,CAUSE_OF_DEATH
was,O
screened,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
after,O
travelling,O
back,O
from,O
Scotland,COUNTRY
.,O
She,O
tested,O
positive,O
for,O
COVID,O
‐,O
19,NUMBER
and,O
was,O
admitted,O
.,O
Her,O
oxygen,O
saturation,O
was,O
99,PERCENT
%,PERCENT
on,O
room,O
air,O
with,O
a,O
respiratory,O
rate,O
(,O
RR,O
),O
of,O
16,NUMBER
breaths,O
per,O
minute,DURATION
(,O
bpm,O
),O
.,O
Examination,O
of,O
the,O
respira,O
‐,O
tory,O
system,O
was,O
unremarkable,O
.,O
Chest,O
radiograph,O
showed,O
bilateral,O
lower,O
zone,O
air,O
space,O
opacities,O
(,O
Fig.,O
1A,O
),O
.,O
Her,O
Modied,O
Early,O
Warn,O
‐,O
ing,O
Score,O
(,O
MEWS,O
),O
was,O
1,NUMBER
.,O
We,O
proceeded,O
with,O
a,O
high,O
‐,O
resolution,O
com,O
‐,O
puted,O
tomography,O
(,O
HRCT,O
),O
.,O
which,O
showed,O
bilateral,O
peripheral,O
lower,O
zone,O
ground,O
‐,O
glass,O
opacication,O
(,O
GGO,O
),O
(,O
Fig.,O
1B,O
),O
.,O
She,O
was,O
treated,O
with,O
oral,O
hydroxychloroquine,O
(,O
HCQ,O
),O
.,O
azithromycin,O
.,O
and,O
lopinavir,O
/,O
ritonavir,O
.,O
Chest,O
radiograph,O
ve,O
days,DATE
later,DATE
showed,O
signi,O
‐,O
cant,O
improvement,O
of,O
GGO,O
(,O
Fig,O
.,O
1C,O
),O
.,O
COVID,O
‐,O
19,NUMBER
real,O
‐,O
time,O
reverse,O
transcription,O
‐,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
‐,O
PCR,O
),O
test,O
was,O
detect,O
‐,O
ed,O
at,O
day,DURATION
10,NUMBER
of,O
illness,CAUSE_OF_DEATH
and,O
became,O
negative,O
at,O
day,DURATION
14,NUMBER
.,O
She,O
was,O
discharged,O
well,O
.,O
A,O
62,NUMBER
‐,O
year,DURATION
‐,O
old,O
asymptomatic,O
man,O
was,O
admitted,O
af,O
‐,O
ter,TITLE
testing,O
positive,O
for,O
COVID,O
‐,O
19,NUMBER
during,O
contact,O
screening,O
.,O
He,O
was,O
afebrile,O
with,O
RR,O
of,O
20,NUMBER
bpm,O
and,O
oxygen,O
saturation,O
of,O
95,PERCENT
%,PERCENT
on,O
room,O
air,O
.,O
Chest,O
examination,O
was,O
normal,O
.,O
Chest,O
radiograph,O
showed,O
left,O
upper,O
zone,O
peripheral,O
consolidation,O
(,O
Fig.,O
1D,O
),O
.,O
HRCT,O
thorax,O
showed,O
peripheral,O
GGOs,O
involving,O
both,O
the,O
left,O
upper,O
and,O
right,O
lower,O
lobes,O
(,O
Fig.,O
1E,O
),O
.,O
He,O
was,O
treated,O
with,O
HCQ,O
and,O
azithromycin,O
.,O
The,O
MEWS,O
remained,O
at,O
1,NUMBER
point,O
throughout,O
admission,O
.,O
Repeated,O
chest,O
radiograph,O
at,O
day,DURATION
5,NUMBER
showed,O
resolution,O
of,O
the,O
GGOs,O
(,O
Fig,O
.,O
1F,O
),O
.,O
2020,DATE
|,O
Vol.,O
8,NUMBER
|,O
Iss,O
.,O
6,NUMBER
|,O
e00604,O
on,O
behalf,O
of,O
The,O
Asian,NATIONALITY
Pacic,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
Respirology,ORGANIZATION
original,O
work,O
is,O
properly,O
cited,O
.,O
Treating,O
Typhoid,CAUSE_OF_DEATH
Mary,O
of,O
COVID,O
‐,O
19,NUMBER
B.H.,O
Ng,O
et,O
al,O
.,O
(,O
HRCT,O
),O
scans,O
showing,O
both,O
ground,O
‐,O
glass,O
opacication,O
(,O
GGO,O
),O
and,O
consolidation,O
in,O
the,O
three,NUMBER
patients,O
.,O
(,O
C,O
.,O
F,O
.,O
I,O
),O
Repeat,O
chest,O
radiographs,O
showing,O
resolution,O
with,O
treatment,O
.,O
A,O
52,NUMBER
‐,O
year,DURATION
‐,O
old,O
asymptomatic,O
woman,O
tested,O
positive,O
during,O
screening,O
after,O
contact,O
with,O
a,O
COVID,O
‐,O
19,NUMBER
individual,O
.,O
She,O
had,O
a,O
background,O
history,O
of,O
hypertension,CAUSE_OF_DEATH
and,O
was,O
on,O
perindopril,O
4,NUMBER
mg,O
od,O
.,O
Clinical,O
examination,O
revealed,O
a,O
tempera,O
‐,O
ture,O
of,O
37,NUMBER
C,O
.,O
RR,O
of,O
16,NUMBER
bpm,O
.,O
and,O
oxygen,O
saturation,O
of,O
99,PERCENT
%,PERCENT
on,O
room,O
air,O
.,O
Lung,O
examination,O
was,O
clear,O
.,O
Chest,O
radiograph,O
showed,O
air,O
space,O
opacities,O
in,O
the,O
right,O
lower,O
zone,O
(,O
Fig.,O
1G,O
),O
.,O
Her,O
MEWS,O
score,O
was,O
2,NUMBER
.,O
and,O
HRCT,O
thorax,O
showed,O
evidence,O
of,O
bilateral,O
lower,O
zone,O
peripheral,O
GGOs,O
(,O
Fig,O
.,O
1H,O
),O
.,O
She,O
was,O
initiated,O
on,O
HCQ,O
and,O
azithromycin,O
.,O
She,O
recovered,O
well,O
with,O
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
have,O
a,O
wide,O
range,O
of,O
symptoms,O
with,O
the,O
majority,O
presenting,O
with,O
an,O
in,O
‐,O
uenza,O
‐,O
like,O
illness,CAUSE_OF_DEATH
of,O
fever,CAUSE_OF_DEATH
.,O
cough,O
.,O
rhinorrhoea,O
.,O
and,O
sore,O
throat,O
[,O
1,NUMBER
],O
.,O
Less,O
common,O
non,O
‐,O
respiratory,O
symptoms,O
include,O
diarrhoea,CAUSE_OF_DEATH
.,O
anosmia,O
.,O
pericarditis,O
.,O
GuillainBarr,O
syndrome,O
.,O
or,O
acute,O
on,O
behalf,O
of,O
The,O
Asian,NATIONALITY
Pacic,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
Respirology,ORGANIZATION
Treating,ORGANIZATION
Typhoid,ORGANIZATION
Mary,ORGANIZATION
of,O
COVID,O
‐,O
19,NUMBER
B.H.,O
Ng,O
et,O
al,O
.,O
Smoking,CAUSE_OF_DEATH
status,O
Days,DURATION
from,O
testing,O
pos,O
‐,O
itive,O
to,O
admission,O
Clinical,O
ndings,O
on,O
Temperature,O
(,O
C,O
),O
Respirato,O
‐,O
ry,O
rate,O
(,O
bpm,O
),O
O2,O
saturation,O
(,O
in,O
room,O
Blood,O
pressure,O
Heart,O
rate,O
(,O
bpm,O
),O
Laboratory,O
results,O
Total,O
white,O
cell,O
count,TITLE
Absolute,O
lympho,O
‐,O
cyte,O
Absolute,O
monocyte,O
Absolute,O
neutrophil,O
C,O
‐,O
reactive,O
protein,O
(,O
mg,O
/,O
Radiological,O
imaging,O
Chest,O
radiograph,O
Treatment,O
and,O
outcome,O
Drug,O
therapy,O
Lifelong,O
non,O
‐,O
smoker,TITLE
Lifelong,O
non,O
‐,O
smoker,TITLE
Left,O
upper,O
zone,O
peripheral,O
Bilateral,O
lower,O
zone,O
peripheral,O
GGOs,O
Left,O
upper,O
zone,O
peripheral,O
Peripheral,O
GGOs,O
involving,O
both,O
the,O
left,O
upper,O
and,O
right,O
lower,O
lobes,O
Air,O
space,O
opacities,O
in,O
the,O
right,O
lower,O
zone,O
Bi,O
‐,O
lateral,O
lower,O
zone,O
peripheral,O
GGOs,O
400,NUMBER
mg,O
bd,O
Day,DURATION
1,NUMBER
200,NUMBER
mg,O
bd,O
Days,DURATION
210,NUMBER
500,NUMBER
mg,O
od,O
Day,DURATION
1,NUMBER
250,NUMBER
mg,O
od,O
Days,DURATION
25 400/100,NUMBER
mg,O
bd,O
Days,DURATION
110,NUMBER
400,NUMBER
mg,O
bd,O
Day,DURATION
1,NUMBER
200,NUMBER
mg,O
bd,O
Days,DURATION
25,NUMBER
500,NUMBER
mg,O
od,O
Day,DURATION
1,NUMBER
250,NUMBER
mg,O
od,O
Days,DURATION
25,NUMBER
400,NUMBER
mg,O
bd,O
Day,DURATION
1,NUMBER
200,NUMBER
mg,O
bd,O
Days,DURATION
210,NUMBER
500,NUMBER
mg,O
od,O
Day,DURATION
1,NUMBER
250,NUMBER
mg,O
od,O
Days,DURATION
25,NUMBER
on,O
behalf,O
of,O
The,O
Asian,ORGANIZATION
Pacic,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
Respirology,ORGANIZATION
Treating,ORGANIZATION
Typhoid,CAUSE_OF_DEATH
Mary,O
of,O
COVID,O
‐,O
19,NUMBER
B.H.,O
Ng,O
et,O
al,O
.,O
Length,O
of,O
hospital,O
stay,O
Repeated,O
COVID,O
‐,O
19,NUMBER
RT,O
‐,O
PCR,O
test,O
Positive,O
at,O
day,DURATION
10,NUMBER
.,O
Negative,O
at,O
days,DURATION
13,NUMBER
and,O
14,NUMBER
Negative,O
at,O
days,DURATION
10,NUMBER
and,O
13,NUMBER
Negative,O
at,O
days,DURATION
10,NUMBER
and,O
bd,O
.,O
Twice,O
daily,SET
;,O
bpm,O
.,O
breaths,O
per,O
minute,DURATION
;,O
COVID,O
‐,O
19,DATE
.,DATE
2019,DATE
‐,O
novel,O
coronavirus,O
;,O
GGO,O
.,O
ground,O
‐,O
glass,O
opacication,O
;,O
HCQ,O
.,O
hydroxychloro,O
‐,O
quine,O
;,O
HRCT,O
.,O
high,O
‐,O
resolution,O
computed,O
tomography,O
;,O
LDH,ORGANIZATION
.,O
lactate,O
dehydrogenase,O
;,O
MEWS,O
.,O
Modied,O
Early,O
Warning,O
Score,O
;,O
RT,O
‐,O
PCR,O
.,O
reverse,O
transcription,O
‐,O
polymerase,O
chain,O
reaction,O
.,O
necrotizing,O
en,O
‐,O
cephalopathy,O
[,O
2.3,NUMBER
],O
.,O
Observational,O
studies,O
have,O
reported,O
up,O
to,O
12,PERCENT
%,PERCENT
of,O
transmissions,O
occurring,O
before,O
the,O
onset,O
of,O
clinical,O
symptoms,O
[,O
4,NUMBER
],O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
patients,O
can,O
be,O
asymptomatic,O
[,O
5.6,NUMBER
],O
.,O
All,O
three,NUMBER
patients,O
in,O
our,O
case,O
series,O
displayed,O
no,O
symptoms,O
of,O
COVID19,O
dis,O
‐,O
ease,O
despite,O
showing,O
radiological,O
evidence,O
of,O
pneumonia,CAUSE_OF_DEATH
.,O
With,O
the,O
absence,O
of,O
symptoms,O
.,O
these,O
patients,O
may,O
not,O
have,O
voluntarily,O
come,O
forward,O
for,O
screening,O
.,O
Screening,O
based,O
on,O
symptoms,O
alone,O
may,O
miss,O
a,O
signicant,O
amount,O
of,O
asymptomatic,O
COVID,O
‐,O
positive,O
patients,O
.,O
Targeted,O
screening,O
in,O
these,O
patients,O
have,O
allowed,O
immediate,O
iso,O
‐,O
lation,O
from,O
the,O
community,O
and,O
initiation,O
of,O
treatment,O
which,O
may,O
have,O
prevented,O
disease,CAUSE_OF_DEATH
progression,O
and,O
achieved,O
earlier,O
recovery,O
.,O
The,O
common,O
laboratory,O
abnormalities,O
are,O
lymphopenia,O
.,O
increased,O
lactate,O
dehydrogenase,O
.,O
and,O
elevated,O
C,O
‐,O
reactive,O
protein,O
[,O
7,NUMBER
],O
.,O
These,O
parameters,O
are,O
non,O
‐,O
specic,O
and,O
their,O
clinical,O
usefulness,O
is,O
limit,O
‐,O
ed,O
.,O
These,O
abnormalities,O
may,O
be,O
related,O
to,O
the,O
cytokine,O
storm,CAUSE_OF_DEATH
in,O
COVID,O
‐,O
19,NUMBER
and,O
the,O
changes,O
are,O
similar,O
to,O
patients,O
with,O
SARS,O
and,O
MERS,O
.,O
We,O
performed,O
the,O
initial,O
imaging,O
tool,O
of,O
chest,O
radiograph,O
which,O
showed,O
varying,O
locations,O
of,O
pneumonia,CAUSE_OF_DEATH
(,O
Fig.,O
1,NUMBER
),O
.,O
As,O
COVID,O
‐,O
19,NUMBER
is,O
a,O
novel,O
disease,CAUSE_OF_DEATH
.,O
we,O
chose,O
to,O
proceed,O
with,O
a,O
HRCT,O
to,O
allow,O
fur,O
‐,O
ther,O
clarication,O
on,O
the,O
extent,O
of,O
the,O
pathologies,O
.,O
We,O
found,O
GGO,O
with,O
peripheral,O
distribution,O
and,O
upper,O
and,O
lower,O
lobes,O
predomi,O
‐,O
nance,O
in,O
our,O
patients,O
.,O
Our,O
ndings,O
are,O
similar,O
with,O
the,O
known,O
ini,O
‐,O
tial,O
computed,O
tomography,O
(,O
CT,STATE_OR_PROVINCE
),O
manifestations,O
of,O
COVID,O
‐,O
19,NUMBER
[,O
8,NUMBER
],O
.,O
The,O
most,O
common,O
reported,O
CT,STATE_OR_PROVINCE
ndings,O
are,O
isolated,O
GGO,O
or,O
a,O
combination,O
of,O
GGO,O
and,O
consolidative,O
opacities,O
[,O
8,NUMBER
],O
.,O
Less,O
common,O
ndings,O
in,O
‐,O
clude,O
interlobular,O
septal,O
thickening,O
.,O
bronchiectasis,O
.,O
pleural,O
ef,O
‐,O
fusion,O
.,O
pleural,O
thickening,O
.,O
and,O
subpleural,O
involvement,O
.,O
cavita,O
‐,O
tion,O
and,O
lymphadenopathy,O
[,O
8,NUMBER
],O
.,O
On,O
average,O
.,O
CT,STATE_OR_PROVINCE
ndings,O
are,O
most,O
prominent,O
on,O
day,DURATION
10,NUMBER
of,O
illness,CAUSE_OF_DEATH
and,O
improve,O
after,O
day,DURATION
14,NUMBER
[,O
9,NUMBER
],O
.,O
In,O
a,O
study,O
including,O
nine,NUMBER
hospitals,O
from,O
the,O
region,O
of,O
rate,O
to,O
be,O
higher,O
from,O
studies,O
in,O
Wuhan,CITY
.,O
the,O
epicentre,O
of,O
this,O
outbreak,O
.,O
with,O
lower,O
prevalence,O
of,O
death,O
among,O
patients,O
from,O
outside,O
Wuhan,CITY
.,O
They,O
also,O
found,O
that,O
older,O
patients,O
with,O
comorbidities,O
may,O
have,O
a,O
more,O
severe,O
impact,O
from,O
the,O
disease,CAUSE_OF_DEATH
[,O
11,NUMBER
],O
.,O
All,O
three,NUMBER
patients,O
in,O
our,O
report,O
had,O
a,O
negative,O
RT,O
‐,O
PCR,O
test,O
by,O
day,DURATION
13,NUMBER
of,O
illness,CAUSE_OF_DEATH
.,O
A,O
study,O
reported,O
a,O
median,O
of,O
36,DURATION
days,DURATION
from,O
the,O
date,O
of,O
symptoms,O
to,O
the,O
date,O
of,O
rst,O
negative,O
RT,O
‐,O
PCR,O
test,O
.,O
with,O
the,O
longest,O
reported,O
at,O
45,DURATION
days,DURATION
from,O
symptom,O
onset,O
[,O
10,NUMBER
],O
.,O
More,O
recent,O
studies,O
have,O
shown,O
that,O
pharyngeal,O
virus,O
shedding,O
does,O
not,O
equate,O
to,O
infectiv,O
‐,O
ity,O
.,O
This,O
shedding,O
appears,O
to,O
peak,O
at,O
day,DURATION
4,NUMBER
and,O
is,O
the,O
highest,O
during,O
the,O
rst,O
week,DURATION
of,O
symptoms,O
[,O
12,NUMBER
],O
.,O
This,O
case,O
series,O
describes,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
pneumonia,CAUSE_OF_DEATH
patterns,O
in,O
asymptomatic,O
individuals,O
.,O
The,O
common,O
CT,STATE_OR_PROVINCE
thorax,O
patterns,O
found,O
are,O
peripheral,O
GGO,O
with,O
upper,O
or,O
lower,O
lobe,O
predominance,O
.,O
We,O
believe,O
screening,O
for,O
COVID,O
‐,O
19,NUMBER
in,O
high,O
‐,O
risk,O
individuals,O
is,O
important,O
to,O
see,O
the,O
extent,O
of,O
pulmonary,O
damage,O
and,O
assess,O
the,O
possible,O
need,O
for,O
long,O
‐,O
term,O
lung,O
function,O
follow,O
‐,O
up,O
.,O
Disclosure,O
Statement,O
Appropriate,O
written,O
informed,O
consent,O
was,O
obtained,O
for,O
publication,O
of,O
this,O
case,O
series,O
and,O
ac,O
‐,O
companying,O
images,O
.,O
At,O
the,O
time,DATE
this,O
report,O
was,O
accepted,O
for,O
pub,O
‐,O
lication,O
.,O
the,O
1,NUMBER
.,O
Guan,O
W,O
‐,O
J,O
.,O
Ni,MISC
Z,O
‐,O
Y,O
.,O
Hu,O
Y,O
.,O
et,O
al,O
.,O
2020,DATE
.,O
Clinical,O
characteristics,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
in,O
China,COUNTRY
.,O
N.,PERSON
Engl,PERSON
.,O
J.,O
Med,O
.,O
2,NUMBER
.,O
Pan,O
L,O
.,O
Mu,O
M,O
.,O
Yang,PERSON
P,O
.,O
et,O
al.,O
2020,DATE
.,O
Clinical,O
characteris,O
‐,O
tics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
digestive,O
symptoms,O
in,O
Hubei,STATE_OR_PROVINCE
.,O
Chi,O
‐,O
na,O
:,O
a,O
descriptive,O
.,O
cross,O
‐,O
sectional,O
.,O
multicenter,O
study,O
.,O
Am,O
.,O
J.,O
Gastroenterol,O
.,O
115,NUMBER
(,O
5,NUMBER
),O
:,O
766773,NUMBER
.,O
3,NUMBER
.,O
Sedaghat,O
Z,O
.,O
and,O
Karimi,PERSON
N.,O
2020,DATE
.,O
Guillain,PERSON
Barre,PERSON
syndrome,O
associated,O
with,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
:,O
a,O
case,O
report,O
.,O
J.,PERSON
Clin,PERSON
.,O
4,NUMBER
.,O
Qian,PERSON
G,PERSON
.,O
Yang,PERSON
N,PERSON
.,O
Ma,ORGANIZATION
AHY,ORGANIZATION
.,O
et,O
al.,O
2020,DATE
.,O
A,O
COVID,O
‐,O
19,NUMBER
transmission,O
within,O
a,O
family,O
cluster,O
by,O
presymptomatic,O
infectors,O
on,O
behalf,O
of,O
The,O
Asian,ORGANIZATION
Pacic,ORGANIZATION
Society,ORGANIZATION
of,ORGANIZATION
Respirology,ORGANIZATION
Treating,O
Typhoid,CAUSE_OF_DEATH
Mary,O
of,O
COVID,O
‐,O
19,NUMBER
B.H.,O
Ng,O
et,O
al,O
.,O
Day,DURATION
M.,O
2020,DATE
.,O
Covid,O
‐,O
19,NUMBER
:,O
identifying,O
and,O
isolating,O
asymptomatic,O
people,O
helped,O
eliminate,O
virus,O
in,O
Italian,NATIONALITY
village,O
.,O
BMJ,O
368,NUMBER
:,O
m1165,O
.,O
Tian,PERSON
S,PERSON
.,O
Hu,O
N,O
.,O
Lou,PERSON
J,PERSON
.,O
et,O
al.,O
2020,DATE
.,O
Characteristics,O
of,O
COVID19,O
infection,CAUSE_OF_DEATH
in,O
Bei,O
‐,O
jing,O
.,O
J.,O
Infect,O
.,O
80,NUMBER
(,O
4,NUMBER
),O
:,O
401406,NUMBER
.,O
Salehi,PERSON
S,O
.,O
Abedi,PERSON
A,O
.,O
Balakrishnan,PERSON
S,O
.,O
et,O
al.,O
2020,DATE
.,O
Coronavirus,MISC
Pan,MISC
F,MISC
.,O
Ye,PERSON
T,PERSON
.,O
Sun,O
P,O
.,O
et,O
al.,O
2020,DATE
.,O
Time,O
course,O
of,O
lung,O
changes,O
on,O
chest,O
CT,STATE_OR_PROVINCE
during,O
recovery,O
from,O
2019,DATE
nov,DATE
‐,O
el,O
coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
pneumonia,CAUSE_OF_DEATH
.,O
Radiology,O
.,O
295,NUMBER
(,O
3,NUMBER
),O
:,O
715721,NUMBER
.,O
9,NUMBER
.,O
Xiao,PERSON
AT,PERSON
.,O
Tong,PERSON
YX,PERSON
.,O
and,O
Zhang,O
S.,O
2020,DATE
.,O
False,O
‐,O
negative,O
of,O
10,NUMBER
.,O
Liu,PERSON
K,O
.,O
Fang,ORGANIZATION
YY,ORGANIZATION
.,O
Deng,PERSON
Y,PERSON
.,O
et,O
al.,O
2020,DATE
.,O
Clinical,O
characteristics,O
of,O
nov,DATE
‐,O
el,O
coronavirus,O
cases,O
in,O
tertiary,O
hospitals,O
in,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
.,O
Chin,PERSON
.,O
Med,O
.,O
J.,O
133,NUMBER
(,O
9,NUMBER
),O
:,O
10251031,NUMBER
.,O
11,NUMBER
.,O
Fu,O
L,O
.,O
Wang,PERSON
B,PERSON
.,O
Yuan,O
T,O
.,O
et,O
al,O
.,O
2020,DATE
.,O
Clinical,O
characteristics,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
China,COUNTRY
:,O
a,O
systematic,O
12,NUMBER
.,O
Wlfel,PERSON
R,PERSON
.,O
Corman,PERSON
VM,PERSON
.,O
Gugge,O
‐,O
mos,DURATION
W,O
.,O
et,O
al.,O
2020,DATE
.,O
Virological,O
assessment,O
of,O
hospitalized,O
pa,O
‐,O
tients,O
with,O
COVID,O
‐,O
2019,DATE
.,O
on,O
behalf,O
of,O
The,O
Asian,NATIONALITY
Pacic,O
Society,O
of,O
Respirology,O
